Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2021 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling. The key is whether management's forward account is substantially about the growth/expansion of specific customers/partners that the company already supplies, with that growth being early and large relative to the company. Let's analyze the transcript. Management discusses various topics: cost reset, portfolio review, investments, orders, supply chain challenges, etc. They talk about end markets, orders, and specific projects. They mention OSI acquisition, funnel, etc. Do they narrate specific counterparties' own trajectories? They mention "life sciences, food and beverage and medical markets" but that's broad. They mention "PureCycle Technologies" as a partner for recycling, but that's a partnership for a project, not necessarily a scaling counterparty. They mention "Department of Energy" collaboration. They mention "OSI" acquisition and its performance. They mention "our lead customer" not really. They talk about "KOB3 activity" and "MRO spend" but that's general. They mention "our OEM customers, the trains and carriers of the world" in context of residential AC, but that's about demand. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves? Looking at the transcript, management talks about their own actions: cost reset, investments, new products (Copeland K7, Greenlee, Gemini, Plantweb Optics). They talk about market conditions, supply chain, orders. They mention "life sciences momentum" but not specific counterparties' scaling. They mention "PureCycle Technologies" as a partner, but that's a single agreement, not a scaling trajectory. They mention "OSI" acquisition and its funnel, but that's about their own business. They do mention "our customers" in general, but not specific identifiable counterparties with their own ramps. They mention "the trains and carriers of the world" but that's vague.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.